tiprankstipranks
BioNTech SE (CH:22UA)
:22UA
Switzerland Market
22UA
BioNTech SE
RESEARCH TOOLSreports

BioNTech SE (22UA) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

22UA Analyst Ratings

Strong Buy
12Ratings
Strong Buy
10 Buy
2 Hold
0 Sell
Based on 12 analysts giving stock ratings to
BioNTech
SE
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

22UA Stock 12 Month Forecast

Average Price Target

CHF100.76
▲(32.56% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is CHF100.76 with a high forecast of CHF114.84 and a low forecast of CHF74.40. The average price target represents a 32.56% change from the last price of CHF76.01.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"69":"CHF69","92":"CHF92","115":"CHF115","80.5":"CHF80.5","103.5":"CHF103.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":114.8417616,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF114.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100.756123,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF100.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74.4045216,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF74.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[69,80.5,92,103.5,115],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.595,78.61398166153846,81.63296332307692,84.65194498461538,87.67092664615384,90.6899083076923,93.70888996923077,96.72787163076923,99.74685329230769,102.76583495384615,105.78481661538461,108.80379827692308,111.82277993846154,{"y":114.8417616,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.595,77.530471,79.465942,81.401413,83.336884,85.272355,87.207826,89.143297,91.078768,93.014239,94.94971,96.885181,98.820652,{"y":100.756123,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.595,75.50342473846153,75.41184947692308,75.32027421538461,75.22869895384615,75.1371236923077,75.04554843076923,74.95397316923076,74.8623979076923,74.77082264615385,74.67924738461538,74.58767212307691,74.49609686153846,{"y":74.4045216,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":70.855,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.855,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.316,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.595,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF114.84Average Price TargetCHF100.76Lowest Price TargetCHF74.40
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on CH:22UA
Terence Flynn
Morgan Stanley
Morgan Stanley
CHF93.01
Buy
22.36%
Upside
Assigned
08/10/26
Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)
J.P. Morgan Analyst forecast on CH:22UA
Jessica Fye
J.P. Morgan
J.P. Morgan
CHF74.4
Hold
-2.11%
Downside
Reiterated
08/06/26
J.P. Morgan Keeps Their Hold Rating on BioNTech SE (BNTX)
Wells Fargo Analyst forecast on CH:22UA
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
CHF113.22
Buy
48.96%
Upside
Reiterated
08/05/26
Wells Fargo Remains a Buy on BioNTech SE (BNTX)
Evercore ISI Analyst forecast on CH:22UA
Cory Kasimov
Evercore ISI
Evercore ISI
CHF109.18→CHF105.14
Buy
38.32%
Upside
Reiterated
08/05/26
BioNTech price target lowered to $130 from $135 at Evercore ISIBioNTech price target lowered to $130 from $135 at Evercore ISI
Citi Analyst forecast on CH:22UA
Geoff Meacham
Citi
Citi
CHF105.14→CHF101.09
Buy
33.00%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), BioNTech SE (NASDAQ: BNTX) and Henry Schein (NASDAQ: HSIC)
BMO Capital Analyst forecast on CH:22UA
Evan Seigerman
BMO Capital
BMO Capital
CHF103.52
Buy
36.19%
Upside
Reiterated
08/05/26
BMO Capital Remains a Buy on BioNTech SE (BNTX)
Berenberg Bank Analyst forecast on CH:22UA
Harry Gillis
Berenberg Bank
Berenberg Bank
CHF113.22→CHF106.75
Buy
40.45%
Upside
Reiterated
08/05/26
Analysts Are Bullish on Top Healthcare Stocks: BioNTech SE (BNTX), Pfizer (PFE)
Canaccord Genuity Analyst forecast on CH:22UA
John Newman
Canaccord Genuity
Canaccord Genuity
CHF127.78→CHF114.84
Buy
51.09%
Upside
Assigned
08/05/26
BioNTech price target raised to $142 from $138 at CanaccordBioNTech price target raised to $142 from $138 at Canaccord
Jefferies Analyst forecast on CH:22UA
Akash Tewari
Jefferies
Jefferies
CHF111.61
Buy
46.83%
Upside
Reiterated
08/04/26
Jefferies Sticks to Their Buy Rating for BioNTech SE (BNTX)
Bank of America Securities Analyst forecast on CH:22UA
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF101.09→CHF98.67
Buy
29.81%
Upside
Reiterated
08/04/26
BioNTech: New Leadership and Advancing Oncology Pipeline Underpin Buy Rating Despite Lowered Price Target to $122
UBS Analyst forecast on CH:22UA
David Dai
UBS
UBS
CHF109.18
Buy
43.64%
Upside
Reiterated
08/04/26
BioNTech: Oncology Pipeline, Strong Leadership, and Cash Balance Support Buy Rating with Unchanged $135 Price Target
Bernstein Analyst forecast on CH:22UA
Jeffrey Walch
Bernstein
Bernstein
CHF77.64
Hold
2.14%
Upside
Reiterated
08/04/26
Bernstein Sticks to Their Hold Rating for BioNTech SE (BNTX)
TD Cowen Analyst forecast on CH:22UA
Yaron Werber
TD Cowen
TD Cowen
CHF76.02
Hold
0.02%
Upside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), BioNTech SE (NASDAQ: BNTX) and Cogent Biosciences (NASDAQ: COGT)
Goldman Sachs Analyst forecast on CH:22UA
Asad Haider
Goldman Sachs
Goldman Sachs
CHF106.75→CHF107.56
Buy
41.51%
Upside
Reiterated
05/05/26
BioNTech SE (BNTX) Receives a Buy from Goldman Sachs
H.C. Wainwright Analyst forecast on CH:22UA
Robert Burns
H.C. Wainwright
H.C. Wainwright
CHF105.14
Buy
38.32%
Upside
Reiterated
04/27/26
Analyst Reiterates Buy on BioNTech, Maintains $130 Price Target on Strength of Pumitamig Oncology Pipeline
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on CH:22UA
Terence Flynn
Morgan Stanley
Morgan Stanley
CHF93.01
Buy
22.36%
Upside
Assigned
08/10/26
Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)
J.P. Morgan Analyst forecast on CH:22UA
Jessica Fye
J.P. Morgan
J.P. Morgan
CHF74.4
Hold
-2.11%
Downside
Reiterated
08/06/26
J.P. Morgan Keeps Their Hold Rating on BioNTech SE (BNTX)
Wells Fargo Analyst forecast on CH:22UA
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
CHF113.22
Buy
48.96%
Upside
Reiterated
08/05/26
Wells Fargo Remains a Buy on BioNTech SE (BNTX)
Evercore ISI Analyst forecast on CH:22UA
Cory Kasimov
Evercore ISI
Evercore ISI
CHF109.18→CHF105.14
Buy
38.32%
Upside
Reiterated
08/05/26
BioNTech price target lowered to $130 from $135 at Evercore ISIBioNTech price target lowered to $130 from $135 at Evercore ISI
Citi Analyst forecast on CH:22UA
Geoff Meacham
Citi
Citi
CHF105.14→CHF101.09
Buy
33.00%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), BioNTech SE (NASDAQ: BNTX) and Henry Schein (NASDAQ: HSIC)
BMO Capital Analyst forecast on CH:22UA
Evan Seigerman
BMO Capital
BMO Capital
CHF103.52
Buy
36.19%
Upside
Reiterated
08/05/26
BMO Capital Remains a Buy on BioNTech SE (BNTX)
Berenberg Bank Analyst forecast on CH:22UA
Harry Gillis
Berenberg Bank
Berenberg Bank
CHF113.22→CHF106.75
Buy
40.45%
Upside
Reiterated
08/05/26
Analysts Are Bullish on Top Healthcare Stocks: BioNTech SE (BNTX), Pfizer (PFE)
Canaccord Genuity Analyst forecast on CH:22UA
John Newman
Canaccord Genuity
Canaccord Genuity
CHF127.78→CHF114.84
Buy
51.09%
Upside
Assigned
08/05/26
BioNTech price target raised to $142 from $138 at CanaccordBioNTech price target raised to $142 from $138 at Canaccord
Jefferies Analyst forecast on CH:22UA
Akash Tewari
Jefferies
Jefferies
CHF111.61
Buy
46.83%
Upside
Reiterated
08/04/26
Jefferies Sticks to Their Buy Rating for BioNTech SE (BNTX)
Bank of America Securities Analyst forecast on CH:22UA
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF101.09→CHF98.67
Buy
29.81%
Upside
Reiterated
08/04/26
BioNTech: New Leadership and Advancing Oncology Pipeline Underpin Buy Rating Despite Lowered Price Target to $122
UBS Analyst forecast on CH:22UA
David Dai
UBS
UBS
CHF109.18
Buy
43.64%
Upside
Reiterated
08/04/26
BioNTech: Oncology Pipeline, Strong Leadership, and Cash Balance Support Buy Rating with Unchanged $135 Price Target
Bernstein Analyst forecast on CH:22UA
Jeffrey Walch
Bernstein
Bernstein
CHF77.64
Hold
2.14%
Upside
Reiterated
08/04/26
Bernstein Sticks to Their Hold Rating for BioNTech SE (BNTX)
TD Cowen Analyst forecast on CH:22UA
Yaron Werber
TD Cowen
TD Cowen
CHF76.02
Hold
0.02%
Upside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), BioNTech SE (NASDAQ: BNTX) and Cogent Biosciences (NASDAQ: COGT)
Goldman Sachs Analyst forecast on CH:22UA
Asad Haider
Goldman Sachs
Goldman Sachs
CHF106.75→CHF107.56
Buy
41.51%
Upside
Reiterated
05/05/26
BioNTech SE (BNTX) Receives a Buy from Goldman Sachs
H.C. Wainwright Analyst forecast on CH:22UA
Robert Burns
H.C. Wainwright
H.C. Wainwright
CHF105.14
Buy
38.32%
Upside
Reiterated
04/27/26
Analyst Reiterates Buy on BioNTech, Maintains $130 Price Target on Strength of Pumitamig Oncology Pipeline
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioNTech SE

3 Months
John NewmanCanaccord Genuity
Success Rate
10/14 ratings generated profit
71%
Average Return
+5.29%
Copying John Newman's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +5.29% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
12/24 ratings generated profit
50%
Average Return
+1.41%
Copying Robert Burns's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +1.41% per trade.
2 Years
Robert BurnsH.C. Wainwright
Success Rate
11/24 ratings generated profit
46%
Average Return
-3.53%
Copying Robert Burns's trades and holding each position for 2 Years would result in 45.83% of your transactions generating a profit, with an average return of -3.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

22UA Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
9
14
9
8
6
Buy
16
19
12
10
11
Hold
3
5
6
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
38
27
23
21
In the current month, 22UA has received 17 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. 22UA average Analyst price target in the past 3 months is 100.76.
Each month's total comprises the sum of three months' worth of ratings.

22UA Financial Forecast

22UA Earnings Forecast

Next quarter’s earnings estimate for 22UA is CHF0.69 with a range of -CHF0.02 to CHF1.27. The previous quarter’s EPS was -CHF3.03. 22UA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 45.83% of the time in the same period. In the last calendar year 22UA has Performed in-line its overall industry.
Next quarter’s earnings estimate for 22UA is CHF0.69 with a range of -CHF0.02 to CHF1.27. The previous quarter’s EPS was -CHF3.03. 22UA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 45.83% of the time in the same period. In the last calendar year 22UA has Performed in-line its overall industry.

22UA Sales Forecast

Next quarter’s sales forecast for 22UA is CHF988.97M with a range of CHF793.35M to CHF1.13B. The previous quarter’s sales results were CHF99.30M. 22UA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 59.72% of the time in the same period. In the last calendar year 22UA has Performed in-line its overall industry.
Next quarter’s sales forecast for 22UA is CHF988.97M with a range of CHF793.35M to CHF1.13B. The previous quarter’s sales results were CHF99.30M. 22UA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 59.72% of the time in the same period. In the last calendar year 22UA has Performed in-line its overall industry.

22UA Stock Forecast FAQ

What is CH:22UA’s average 12-month price target, according to analysts?
Based on analyst ratings, BioNTech SE’s 12-month average price target is 100.76.
    What is CH:22UA’s upside potential, based on the analysts’ average price target?
    BioNTech SE has 32.56% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BioNTech SE a Buy, Sell or Hold?
          BioNTech SE has a consensus rating of Strong Buy, which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.
            What is BioNTech SE’s share price target?
            The average share price target for BioNTech SE is 100.76. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF114.84 ,and the lowest forecast is CHF74.40. The average share price target represents 32.56% Increase from the current price of CHF76.01.
              What do analysts say about BioNTech SE?
              BioNTech SE’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of BioNTech SE?
                To buy shares of CH:22UA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.